Authors/Creators: |
- Mainz, J.G.
- Zagoya, C.
- Polte, L.
- Naehrlich, L.
- Sasse, L.
- Eickmeier, O.
- Smaczny, C.
- Barucha, A.
- Bechinger, L.
- Duckstein, F.
- Kurzidim, L.
- Eschenhagen, P.
- Caley, L. https://orcid.org/0000-0001-8957-1018
- Peckham, D. https://orcid.org/0000-0001-7723-1868
- Schwarz, C.
|
Commentary on: |
Mainz, JG, Zagoya, C, Polte, L et al. (12 more authors)
(2022)
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Frontiers in Pharmacology, 13.
877118.
ISSN 1663-9812
|
Copyright, Publisher and Additional Information: |
© 2023 Mainz, Zagoya, Polte, Naehrlich, Sasse, Eickmeier, Smaczny, Barucha, Bechinger, Duckstein, Kurzidim, Eschenhagen, Caley, Peckham and Schwarz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
Keywords: |
gastrointestinal; patient reported outcome measure; CFTR modulators; elexacaftor; symptom score |
Dates: |
- Accepted: 21 April 2023
- Published (online): 3 May 2023
- Published: 3 May 2023
|
Institution: |
The University of Leeds |
Academic Units: |
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Molecular Medicine |
Depositing User: |
Symplectic Publications |
Date Deposited: |
20 Dec 2023 14:02 |
Last Modified: |
20 Dec 2023 14:11 |
Published Version: |
https://www.frontiersin.org/articles/10.3389/fphar... |
Status: |
Published |
Publisher: |
Frontiers Media |
Identification Number: |
https://doi.org/10.3389/fphar.2023.1207356 |
Related URLs: |
|